stockrow
Friday 6 November 2026
Export MBX’s income statement to Excel — free account
MBX Biosciences, Inc.
- EPS
- −34.5%
- Free cash flow
- −29.7%
Quarter to June 2026, against a year earlier
51.90
3.44
+7.10%
Follow MBX
Alert me
MBX Biosciences, Inc. (MBX) Return on equity
MBX Biosciences, Inc.'s return on equity over the twelve months to 30 June 2026 was −33.2%, down 5.4 percentage points from fiscal 2025 (−27.8%). That is above the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −27.8% | 39.19 |
| FY2024 | −67.0% | (123.55) |
| FY2023 | 56.6% | 56.60 |
| FY2022 | 0.00% | — |
Return on equity against peers
| Company | Return on equity |
|---|---|
| ADMA ADMA Biologics Inc compare | 42.0% |
| XNCR Xencor, Inc. compare | −29.1% |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −30.0% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −30.2% |
| MBX MBX Biosciences, Inc. | −33.2% |
| CLDX Celldex Therapeutics, Inc. compare | −43.9% |
| RXRX Recursion Pharmaceuticals, Inc. compare | −48.7% |
| PHVS Pharvaris N.V. compare | −71.5% |
| RCUS Arcus Biosciences, Inc. compare | −114.1% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)